Sanofi/Regeneron and Amgen race ahead in PCSK9 inhibitors on positive early data
This article was originally published in Scrip
Executive Summary
Interest in inhibiting PCSK9 as a new therapeutic avenue in hypercholesterolaemia is gathering momentum on the back of promising clinical results reported this week showing reductions in LDL-cholesterol of over 70% with two potential drug offerings.